Core Insights - Pfizer reported its fourth-quarter earnings, exceeding Wall Street expectations, driven by strong demand for classic drugs like Apixaban and Vyndaqel [1][1]. Financial Performance - Adjusted earnings per share for Pfizer in the fourth quarter were $0.66, surpassing analysts' expectations of $0.57 [1][1].